Sign up
Pharma Capital

Living Cell Technologies maps timeline to clinical results from Parkinson's trial

The halt will remain in place until Monday 13th November 2017.
The company's shares are in pre-open

Living Cell Technologies Ltd (ASX:LCT) is preparing some highly anticipated results from the NTCELL Parkinson's disease clinical trial, which are expected on Friday 10th November 2017.

Shares in the company had been rising on the anticipation, recently hitting $0.28, but have lost some momentum and were changing hands at $0.205 at yesterday's close.

Mid-year shares could have been snapped up around the $0.11 range.

The ASX has this morning granted Living Cell a trading halt to prepare details from the trial.

The halt will remain in place until the opening of trade on Monday 13th November 2017, or earlier if an announcement is made to the market.

Register here to be notified of future LCT Company articles
View full LCT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.